Invex Therapeutics (ASX:IXC) Intangible Assets: A$0.00 Mil (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
38 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Intangible Assets?

Invex Therapeutics ASX:IXC 38 Intangible Assets is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Invex Therapeutics's intangible assets for the quarter that ended in Dec. 2025 was A$0.00 Mil.


Invex Therapeutics  (ASX:IXC) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Invex Therapeutics Intangible Assets Related Terms


Invex Therapeutics Intangible Assets Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Intangible Assets Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Intangible Assets
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:IXC
38GF Score
Invex Therapeutics Ltd ASX:IXC
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Intangible Assets of A$0.00 Mil as of Dec. 2025. Intangible assets include patents, goodwill and trade secrets. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Intangible Assets too high?
Invex Therapeutics' current Intangible Assets is A$0.00 Mil. Overall, Invex Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Intangible Assets compare to VRTX and REGN?
Invex Therapeutics' Intangible Assets of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Intangible Assets is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Intangible Assets of A$0.00 Mil. The current Intangible Assets is A$0.00 Mil. Invex Therapeutics' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Intangible Assets is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
38GF Score

Get the complete analysis for ASX:IXC

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price